Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Who May Qualify: - Adults receiving first cycle of blinatumomab for relapse/refractory or MRD-positive B-cell Acute Lymphoblastic Leukemia - Adequate renal and hepatic function - Negative for HIV - Negative serum pregnancy test, if applicable - ECOG 0-2 Who Should NOT Join This Trial: - Active CNS involvement by ALL - Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder) - Contraindication to receive intrathecal methotrexate - Prior treatment with blinatumomab - Active malignancy other than ALL - Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator Always talk to your doctor about whether this trial is right for you.